Megestrol acetate in unresectable hepatocellular carcinoma

M. Colleoni, P. Nelli, G. Vicario, G. Mastropasqua, P. Manente

Research output: Contribution to journalArticle

Abstract

Aims and background: No consolidated medical treatment has yet been established for unresectable hepatocellular carcinoma (HCC). A possible interference of hormones in the pathogenesis and cellular growth of HCC has been suggested. Methods: To evaluate the activity and tolerance of progestins in HCC, patients were treated with megestrol acetate orally at a dose of 160 mg daily until progression of disease or grade III-IV toxicity was observed. Results: Eleven patients entered the study and were assessable for response and side effects. Median duration of treatment was 80 days (range 60-150). No major responses were observed, 4 patients had stabilization of disease for at least 2 months, and 7 had progressive disease. Median time to disease progression was 3 months (range 2-5). Three patients required interruption of treatment because of toxicity (2 patients had worsening of concomitant diabetes and 1 patient had gastric bleeding). Conclusions: The results of the present study suggest that hormone therapy with megestrol acetate has no significant role in HCC.

Original languageEnglish
Pages (from-to)351-353
Number of pages3
JournalTumori
Volume81
Issue number5
Publication statusPublished - 1995

Fingerprint

Megestrol Acetate
Hepatocellular Carcinoma
Disease Progression
Hormones
Progestins
Therapeutics
Type 1 Diabetes Mellitus
Stomach
Hemorrhage
Growth

Keywords

  • hepatocellular carcinoma
  • megestrol acetate

ASJC Scopus subject areas

  • Cancer Research

Cite this

Colleoni, M., Nelli, P., Vicario, G., Mastropasqua, G., & Manente, P. (1995). Megestrol acetate in unresectable hepatocellular carcinoma. Tumori, 81(5), 351-353.

Megestrol acetate in unresectable hepatocellular carcinoma. / Colleoni, M.; Nelli, P.; Vicario, G.; Mastropasqua, G.; Manente, P.

In: Tumori, Vol. 81, No. 5, 1995, p. 351-353.

Research output: Contribution to journalArticle

Colleoni, M, Nelli, P, Vicario, G, Mastropasqua, G & Manente, P 1995, 'Megestrol acetate in unresectable hepatocellular carcinoma', Tumori, vol. 81, no. 5, pp. 351-353.
Colleoni M, Nelli P, Vicario G, Mastropasqua G, Manente P. Megestrol acetate in unresectable hepatocellular carcinoma. Tumori. 1995;81(5):351-353.
Colleoni, M. ; Nelli, P. ; Vicario, G. ; Mastropasqua, G. ; Manente, P. / Megestrol acetate in unresectable hepatocellular carcinoma. In: Tumori. 1995 ; Vol. 81, No. 5. pp. 351-353.
@article{a042803d632942d8abb7ce0a13e6c2a4,
title = "Megestrol acetate in unresectable hepatocellular carcinoma",
abstract = "Aims and background: No consolidated medical treatment has yet been established for unresectable hepatocellular carcinoma (HCC). A possible interference of hormones in the pathogenesis and cellular growth of HCC has been suggested. Methods: To evaluate the activity and tolerance of progestins in HCC, patients were treated with megestrol acetate orally at a dose of 160 mg daily until progression of disease or grade III-IV toxicity was observed. Results: Eleven patients entered the study and were assessable for response and side effects. Median duration of treatment was 80 days (range 60-150). No major responses were observed, 4 patients had stabilization of disease for at least 2 months, and 7 had progressive disease. Median time to disease progression was 3 months (range 2-5). Three patients required interruption of treatment because of toxicity (2 patients had worsening of concomitant diabetes and 1 patient had gastric bleeding). Conclusions: The results of the present study suggest that hormone therapy with megestrol acetate has no significant role in HCC.",
keywords = "hepatocellular carcinoma, megestrol acetate",
author = "M. Colleoni and P. Nelli and G. Vicario and G. Mastropasqua and P. Manente",
year = "1995",
language = "English",
volume = "81",
pages = "351--353",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Megestrol acetate in unresectable hepatocellular carcinoma

AU - Colleoni, M.

AU - Nelli, P.

AU - Vicario, G.

AU - Mastropasqua, G.

AU - Manente, P.

PY - 1995

Y1 - 1995

N2 - Aims and background: No consolidated medical treatment has yet been established for unresectable hepatocellular carcinoma (HCC). A possible interference of hormones in the pathogenesis and cellular growth of HCC has been suggested. Methods: To evaluate the activity and tolerance of progestins in HCC, patients were treated with megestrol acetate orally at a dose of 160 mg daily until progression of disease or grade III-IV toxicity was observed. Results: Eleven patients entered the study and were assessable for response and side effects. Median duration of treatment was 80 days (range 60-150). No major responses were observed, 4 patients had stabilization of disease for at least 2 months, and 7 had progressive disease. Median time to disease progression was 3 months (range 2-5). Three patients required interruption of treatment because of toxicity (2 patients had worsening of concomitant diabetes and 1 patient had gastric bleeding). Conclusions: The results of the present study suggest that hormone therapy with megestrol acetate has no significant role in HCC.

AB - Aims and background: No consolidated medical treatment has yet been established for unresectable hepatocellular carcinoma (HCC). A possible interference of hormones in the pathogenesis and cellular growth of HCC has been suggested. Methods: To evaluate the activity and tolerance of progestins in HCC, patients were treated with megestrol acetate orally at a dose of 160 mg daily until progression of disease or grade III-IV toxicity was observed. Results: Eleven patients entered the study and were assessable for response and side effects. Median duration of treatment was 80 days (range 60-150). No major responses were observed, 4 patients had stabilization of disease for at least 2 months, and 7 had progressive disease. Median time to disease progression was 3 months (range 2-5). Three patients required interruption of treatment because of toxicity (2 patients had worsening of concomitant diabetes and 1 patient had gastric bleeding). Conclusions: The results of the present study suggest that hormone therapy with megestrol acetate has no significant role in HCC.

KW - hepatocellular carcinoma

KW - megestrol acetate

UR - http://www.scopus.com/inward/record.url?scp=0029586864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029586864&partnerID=8YFLogxK

M3 - Article

C2 - 8804452

AN - SCOPUS:0029586864

VL - 81

SP - 351

EP - 353

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -